Core Insights - Tenaya Therapeutics, Inc. shares have increased due to a positive market reaction to a research collaboration with Alnylam Pharmaceuticals focused on cardiovascular disease treatments [1][2] Group 1: Collaboration Details - The collaboration aims to discover human genetic targets for potential cardiovascular disease treatments, with Tenaya validating up to 15 gene targets [2] - Tenaya will receive up to $10 million in upfront payments, with potential milestone payments reaching up to $1.13 billion [2] Group 2: Tenaya's Capabilities - Tenaya utilizes human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for high-throughput identification of genetic targets and employs human-engineered heart tissue and preclinical in vivo models for validation [3] - The company has identified over 150 genetic targets, contributing to the development of clinical-stage candidates such as TN-201, TN-401, and TN-301, along with several early-stage programs [4] Group 3: Clinical Trials and Data - Interim data from the ongoing RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease was shared in December 2025, including safety and biopsy results from three patients [4][5] Group 4: Alnylam Pharmaceuticals Strategy - Alnylam Pharmaceuticals has announced a five-year roadmap, "Alnylam 2030," focusing on establishing leadership in transthyretin (TTR) diseases and aims to lead the TTR market in revenue by 2030 [6] Group 5: Technical Analysis - Despite recent gains, Tenaya Therapeutics is trading 29.1% below its 100-day SMA and 23.6% below its 200-day SMA, indicating a bearish trend [7] - The stock's RSI is at 40.21, suggesting it is neither overbought nor oversold, while the MACD indicates bearish momentum [7] - Tenaya Therapeutics shares were up 31.20% at 76 cents at the time of publication [7] Group 6: Analyst Ratings - Analysts have given Tenaya Therapeutics a Buy rating, with recent target adjustments from Canaccord Genuity ($5), HC Wainwright & Co. ($3), and Chardan Capital ($8) [8]